UPB · Upstream Bio Inc
United States · RS rating 5 · As of 2026-11-03
| Price | 3.39 USD |
|---|---|
| 1-day change | +1.2% |
| RS rating (overall / 1M / 3M / 12M) | 5 / 12 / 9 / 6 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 18 / 8 / 9 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -24.3% |
| Sales growth Q/Q | -2.2% |
| Distance from 52-week high | +89.6% |
| Market cap (USD) | $522.4M |